Both primary and secondary data sources have been leveraged in the global market research report. Analysis covers market size (US$ 5.03 billion in 2023, forecast US$ 9.03 billion by 2031, CAGR ~7.8%), regulatory momentum (e.g. FDA approval of Zunveyl® in 2024), emerging tolerable formulations (weekly patches, oral prodrugs), regional dynamics (North America leading, Asia‑Pacific faste... https://www.datamintelligence.com/research-report/acetylcholinesterase-inhibitors-market